MAPLE SYRUP URINE DISEASE

Maple Syrup Urine Disease — a branched-chain amino acid metabolic emergency where genotype determines the difference between classic lethal disease and mild intermittent forms manageable with dietary adjustment.

Whole genome sequencing evaluates all three BCKD complex genes — BCKDHA, BCKDHB, and DBT — identifying the specific variant combination that determines disease severity and long-term dietary leucine tolerance.

BCKDHA
BCKDHB
DBT

About this condition

Maple Syrup Urine Disease

Maple syrup urine disease (MSUD) is an autosomal recessive disorder of branched-chain amino acid (BCAA) metabolism caused by deficiency of the branched-chain α-ketoacid dehydrogenase (BCKD) complex. Three genes encode the catalytic subunits: BCKDHA (E1α, chromosome 19q13.2), BCKDHB (E1β, chromosome 6q14.1), and DBT (E2, chromosome 1p21.2). BCKD complex deficiency causes accumulation of leucine, isoleucine, and valine and their corresponding α-ketoacids, producing the characteristic maple syrup odor in urine and cerumen. Classic MSUD affects approximately 1 in 185,000 newborns worldwide, with dramatically elevated prevalence in Old Order Mennonite populations (approximately 1 in 176 births).

Classic MSUD presents as a neonatal emergency: affected newborns appear normal at birth but develop poor feeding, lethargy, and a distinctive sweet odor within 2-3 days. Without immediate treatment, progressive encephalopathy leads to cerebral edema, coma, and death within the first weeks of life. The primary toxic metabolite is leucine — plasma leucine levels are the critical monitoring parameter. Treatment requires immediate BCAA-free formula, lifelong dietary leucine restriction, and emergency metabolic protocols during illness-related catabolism. Liver transplantation provides definitive metabolic correction and is increasingly performed in early childhood.

Variant forms — intermediate, intermittent, and thiamine-responsive MSUD — present later in life with episodic metabolic crises triggered by illness or protein intake. These milder phenotypes retain 3-30% residual BCKD enzyme activity and are determined by specific genotype combinations. Thiamine-responsive MSUD (primarily BCKDHB variants) can be partially managed with pharmacological thiamine supplementation, reducing dietary restriction burden. Identifying the specific MSUD genotype determines disease classification, dietary management intensity, and thiamine responsiveness.

Thiamine-responsive MSUD — primarily caused by specific BCKDHB variants — retains partial enzyme activity that can be enhanced with high-dose thiamine supplementation, reducing the severity of dietary restriction required.

Gene locus: BCKDHA (19q13.2), BCKDHB (6q14.1), DBT (1p21.2)

Newborn screening detects elevated BCAAs but does not identify which gene is affected or predict disease severity. Molecular genotyping determines classic vs. intermediate vs. thiamine-responsive forms — directly affecting treatment approach.

The specific BCKD gene and variant determine whether thiamine supplementation can reduce dietary restriction

Thiamine-responsive MSUD — primarily associated with specific BCKDHB missense variants — retains sufficient residual enzyme activity that high-dose thiamine (100-300mg/day) can meaningfully increase BCKD complex function. For these patients, thiamine supplementation allows higher dietary leucine tolerance, reducing the burden of lifelong BCAA-restricted diet. Without molecular genotyping, thiamine responsiveness must be determined empirically through a therapeutic trial, which delays optimization of the dietary regimen. Whole genome sequencing identifies the specific gene and variant, enabling immediate classification of thiamine-responsive potential.

Carrier screening in high-prevalence populations prevents neonatal metabolic crises before they occur

In Old Order Mennonite communities, MSUD carrier frequency approaches 1 in 7 — meaning approximately 1 in 176 births is affected. The Mennonite founder mutation (BCKDHA p.Tyr438Asn) accounts for the vast majority of alleles in these communities. Carrier screening identifies at-risk couples before pregnancy, enabling prenatal diagnosis and ensuring delivery at centers with immediate metabolic management capability. In broader populations, carrier frequency is approximately 1 in 200-300 — low enough that targeted screening is rarely performed, but common enough that unexpected MSUD births occur regularly. Whole genome sequencing provides carrier status as part of comprehensive preconception genetic evaluation.

Maple Syrup Urine Disease — a branched-chain amino acid metabolic emergency where genotype determines the difference between classic lethal disease and mild intermittent forms manageable with dietary adjustment.

Maple Syrup Urine Disease

Newborn screening detects elevated BCAAs but does not identify which gene is affected or predict disease severity. Molecular genotyping determines classic vs. intermediate vs. thiamine-responsive forms — directly affecting treatment approach.

The specific BCKD gene and variant determine whether thiamine supplementation can reduce dietary restriction

Carrier screening in high-prevalence populations prevents neonatal metabolic crises before they occur

Others in Rare Diseases

One test. A lifetime of answers.